Korean Won Extends Losing Streak to Fourth Session Amid Fed's Hawkish Stance and Risk Aversion

Why Archer and Joby Stocks Are Falling as Oil and Treasury Yields Rise

AstraZeneca’s ATTR-CM Imaging Sub-study Wraps Up, Setting the Stage for New Data Insights

Bond Yields at 5%, Oil at $120, VIX at 25? The Market's Nightmare Scenario Is Rapidly Becoming Reality

Intercont says not commenting on short-term market volatility

Capital Markets Warns of Rising Odds for a U.S. Stock Correction, Citing Midterm Election Risks and AI Trade Instability

Wall Street's Deceptive Calm Meets Bond Market's Stern Warning: As VIX Falls Silent, Are Treasury Yields the New Fear Barometer for Equities?

BridgeBio Pharma presents new analyses from Phase 3 ATTRibute-CM study

Acoramidis Demonstrates Reversal of Cardiac Structural Disease Progression and Functional Decline and Significantly Increases Days Alive and Free from Hospitalization in ATTR-CM

Ionis, AstraZeneca ATTR-CM trial did not meet primary endpoint

Japanese Shares Rise Ahead of Federal Reserve Chair's Rate Outlook; Oil Falls

Bayer’s MOSAIC-TTR Study: Real-World Data Push for Acoramidis in ATTR-CM

BridgeBio Pharma doses first patient in ASCEND-ATTR trial

BridgeBio Announces First Participant Dosed in ASCEND-ATTR, a Phase 3b/4 Study Evaluating the Long-Term Effects of Acoramidis on Disease Regression in ATTR-CM

Alert Signals Intensify: UBS Flags U.S. Stock Market Fragility at Two-Year High, Echoing Pattern That Preceded VIX Spike

Alnylam to present new clinical data on ATTR, hypertension at ESC Congress

BridgeBio to Present New Acoramidis Data from Open-Label Extension Analyses in ATTR-CM at ESC Congress 2026

The Bond Selloff is Rattling Investors, but Here's Why They Shouldn't Expect a Deeper Stock Downturn

Banco Santander receives Federal Reserve approval for Webster acquisition